CSL logo

CSL Limited Stock Price

ASX:CSL Community·AU$104.6b Market Cap
  • 2 Narratives written by author
  • 4 Comments on narratives written by author
  • 403 Fair Values set on narratives written by author

CSL Share Price Performance

AU$220.29
-79.31 (-26.47%)
21.4% undervalued intrinsic discount
AU$280.38
Fair Value
AU$220.29
-79.31 (-26.47%)
21.4% undervalued intrinsic discount
AU$280.38
Fair Value
Price AU$220.29
AnalystConsensusTarget AU$280.38
Ramsee AU$263.33

CSL Community Narratives

AnalystConsensusTarget·
Fair Value AU$280.38 21.4% undervalued intrinsic discount

Operational Improvements Will Unlock Biotech Potential And China Market Expansion

2users have liked this narrative
0users have commented on this narrative
136users have followed this narrative
Ramsee·
Fair Value AU$263.33 16.3% undervalued intrinsic discount

CSL is undervalued in High Tax Scenario

3users have liked this narrative
4users have commented on this narrative
56users have followed this narrative
AU$280.38
21.4% undervalued intrinsic discount
Revenue growth
5.3% p.a.
Profit Margin
22.69%
Future PE
26.36x
Share price in 2028
AU$340.45

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

0 Risks
4 Rewards

CSL Limited Key Details

US$15.6b

Revenue

US$7.5b

Cost of Revenue

US$8.1b

Gross Profit

US$5.1b

Other Expenses

US$3.0b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 09, 2026
6.21
51.93%
19.30%
45.9%
View Full Analysis

About CSL

Founded
1916
Employees
29904
CEO
Paul McKenzie
WebsiteView website
www.csl.com

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Recent CSL News & Updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Recent updates

No updates